MedPath

JANSSEN ORTHO LLC

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:4

Trial Phases

2 Phases

Phase 3:2
Phase 4:2

Drug Approvals

1

SFDA:1

Drug Approvals

ERLEADA 60 mg Film-coated Tablet

Approval Date
Jul 18, 2025
SFDA

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 3
2 (50.0%)
Phase 4
2 (50.0%)

A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches

Phase 3
Completed
Conditions
Migraine
Interventions
First Posted Date
2005-11-22
Last Posted Date
2014-02-21
Lead Sponsor
Janssen-Ortho LLC
Target Recruit Count
447
Registration Number
NCT00257010

Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine

Phase 4
Completed
Conditions
Migraine
Classic Migraine
Common Migraine
First Posted Date
2005-09-21
Last Posted Date
2011-05-17
Lead Sponsor
Janssen-Ortho LLC
Target Recruit Count
406
Registration Number
NCT00210496

A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache

Phase 4
Completed
Conditions
Migraine
First Posted Date
2005-09-21
Last Posted Date
2011-05-17
Lead Sponsor
Janssen-Ortho LLC
Target Recruit Count
378
Registration Number
NCT00210509

A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents

Phase 3
Completed
Conditions
Migraine
First Posted Date
2005-09-21
Last Posted Date
2011-05-17
Lead Sponsor
Janssen-Ortho LLC
Target Recruit Count
866
Registration Number
NCT00210483

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.